Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?

Nature Reviews Cardiology volume 13, pages 623–628 (2016)Cite this article

Subjects

Abstract

Heart failure (HF) is a global epidemic affecting millions of individuals worldwide. Although important progress has been made in the management of HF, this condition remains a common cause of morbidity and death. Since the publication of the previous sets of guidelines for the management of HF, new diagnostic and therapeutic options for HF have emerged. Now, both the ESC and the ACC/AHA/HFSA have simultaneously published an update of their guidelines incorporating, among others, recommendations for the use of new pharmacological therapies for the treatment of HF. For this Viewpoint article, we have asked the chairs of the ESC Task Force, the chairs of the ACC/AHA/HFSA Writing Committee, and an independent opinion leader in the field to offer their expert insight into the new guidelines, highlighting what is new, what the main differences are between the two sets of guidelines, and what steps should be taken to improve the guidelines in future updates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Initial management of a patient with acute heart failure.
Figure 2: Results of diastolic stress testing.

Similar content being viewed by others

References

  1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).

  2. McMurray, J. J. et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).

    Article  Google Scholar 

  3. McMurray, J. J. et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur. Heart J. 36, 434–439 (2015).

    Article  Google Scholar 

  4. Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 18, 891–975 (2016).

    Article  Google Scholar 

  5. Yancy, C. W. et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2016.05.011 (2016).

  6. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–e239 (2013).

    Article  Google Scholar 

  7. Heart Failure Society of America et al. HFSA 2010 comprehensive heart failure practice guideline. J. Card. Fail. 16, e1–e194 (2010).

  8. McMurray, J. J. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 33, 1787–1847 (2012).

    Article  Google Scholar 

  9. Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885 (2010).

    Article  CAS  Google Scholar 

  10. Fitchett, D. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur. Heart J. 37, 1526–1534 (2016).

    Article  CAS  Google Scholar 

  11. Ruschitzka, F. et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 369, 1395–1405 (2013).

    Article  CAS  Google Scholar 

  12. Borlaug, B. A. & Redfield, M. M. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123, 2006–2013 (2011).

    Article  Google Scholar 

  13. Cohn, J. N. Monitoring adherence to guidelines. Circ. Heart Fail. 1, 87–88 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mariell Jessup is at the Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Building 421, Philadelphia, Pennsylvania 19104, USA.,

    Mariell Jessup

  2. Thomas H. Marwick is at Baker-IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia.,

    Thomas H. Marwick

  3. Piotr Ponikowski is at the Department of Heart Disease, Wroclaw Medical University, Centre for Heart Diseases, Military Hospital, ul.Weigla 5, 50–981 Wroclaw, Poland.,

    Piotr Ponikowski

  4. Adriaan A. Voors is at the Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, Netherlands.,

    Adriaan A. Voors

  5. Clyde W. Yancy is at the Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, Feinberg School of Medicine, 676 North St. Clair, Suite 600, Chicago, Illinois 60611, USA.,

    Clyde W. Yancy

Authors
  1. Mariell Jessup
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas H. Marwick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piotr Ponikowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriaan A. Voors
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clyde W. Yancy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to all aspects of this manuscript.

Corresponding authors

Correspondence to Mariell Jessup, Thomas H. Marwick, Piotr Ponikowski, Adriaan A. Voors or Clyde W. Yancy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jessup, M., Marwick, T., Ponikowski, P. et al. 2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?. Nat Rev Cardiol 13, 623–628 (2016). https://doi.org/10.1038/nrcardio.2016.134

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.134

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing